$1.30
-0.02-1.52%
At close: -
$1.33
0.032.31%
After Hours: 4:02 PM EDT
Comments
Loading...
Climb Bio Analyst Ratings and Price Targets | NASDAQ:CLYM | Benzinga
Climb Bio Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Climb Bio Corp from these most-recent analyst ratings.
Analyst Ratings for Climb Bio
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Climb Bio (CLYM) stock?
There is no price target for Climb Bio
What is the most recent analyst rating for Climb Bio (CLYM)?
There is no analyst for Climb Bio
When was the last upgrade for Climb Bio (CLYM)?
There is no last upgrade for Climb Bio
When was the last downgrade for Climb Bio (CLYM)?
There is no last downgrade for Climb Bio.
When is the next analyst rating going to be posted or updated for Climb Bio (CLYM)?
There is no next analyst rating for Climb Bio.
Is the Analyst Rating Climb Bio (CLYM) correct?
There is no next analyst rating for Climb Bio.
Browse analyst ratings and price targets on all stocks.